Randomized Trialhigh evidence
Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Risk TIA: OCEANIC-STROKE Randomized Trial.
Circulation·October 13, 2026·PMID 42866879
Why it mattersFactor XIa inhibition offers a potential strategy to reduce ischemic events without the bleeding penalty typical of conventional anticoagulants. This bleeding-focused analysis reassures that asundexian added to antiplatelet therapy does not significantly increase major bleeding, while highlighting a specific increase in lower gastrointestinal bleeding that may influence monitoring and patient selection.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled